Drugs / GYNORYLAQ-TM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07316361 | Feb 2026 → Dec 2029 expected | endometrial carcinoma | Biogenea Pharmaceuticals Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GYNORYLAQ-TM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07316361 ↗ |
| Modality | Vaccine | “GYNORYLAQ-TM personalized neoantigenic peptide vaccine” NCT07316361 ↗ |
| Route | Subcutaneous | “All selected peptides are synthesized under GMP and formulated for subcutaneous or intradermal administration.” NCT07316361 ↗ |